The medical community has witnessed a staggering transition as cellular engineering moves from experimental curiosity to a cornerstone of modern treatment. The emergence of Chimeric Antigen Receptor (CAR) T-cell therapy has fundamentally altered the oncological landscape, turning once-terminal
Relentless rises in drug-resistant infections have turned routine care into a negotiation with risk that standard antibiotics too often lose, and the search for smarter countermeasures has shifted to tools built by biology itself. Bacterial extracellular vesicles (BEVs) sit at that inflection
The intricate dance of life within a human cell relies on more than just the genetic blueprints stored in the nucleus or the proteins that perform the heavy lifting. For decades, biology textbooks have described the cell membrane as a passive container—a structural scaffold that simply holds
The global medical landscape has reached a critical juncture where the standard pharmacological toolkit is increasingly struggling to contain the spread of hyper-virulent bacterial pathogens. Antimicrobial resistance stands as one of the most significant threats to modern healthcare, potentially
In the landscape of biopharmaceutical innovation, Ivan Kairatov stands as a prominent figure whose work bridges the gap between high-throughput technology and therapeutic application. With a career rooted in deep-tier research and development, Kairatov has dedicated years to understanding how
Chronic obstructive pulmonary disease has long remained a primary cause of global mortality, yet the therapeutic options available to millions of suffering patients have seen little fundamental change for decades. This persistent challenge took a major turn on March 27, 2026, when AstraZeneca
